ABSTRACT
Objective:This paper mainly discusses the expression of hsa_circ_002082 in breast cancer and its clinical significance to breast cancer.Methods:The up-regulated hsa_circ_002082 in breast cancer was screened out through the bioinformatics website, and verified by quantitative reverse transcription PCR (qRT-PCR). The differential expression of hsa_circ_002082 in different clinical index groups was analyzed by one-way ANOVA and t-test, and the ROC curve was used to analyze the value of hsa_circ_002082 in diagnosing breast cancer or identifying clinical indexes.Results:Compared with para-cancerous tissue (1.00±0.21), the expression of hsa_circ_002082 in cancer tissue (1.34±0.25) was higher than that in peripheral blood of healthy people (1.00±0.26), and the expression of hsa_circ_002082 in peripheral blood of breast cancer patients (1.39±0.24) increased (all P<0.05). The AUC value of hsa_circ_002082 for breast cancer diagnosis was 0.8520 ( P<0.05). There were differences in the expression of hsa_circ_002082 in tumor grade, estrogen receptor (ER) positive, carcino-embryonic antigen (CEA) positive, Ki-67 proliferation index, tumor metastasis, and TNM grade (all P<0.05). The relative expression level of hsa_circ_002082 was significantly positively correlated with the level of tumor marker CEA ( r=0.368, P=0.009). The AUC values of hsa_circ_002082 for distinguishing tumor grade, ER positive, CEA positive, Ki-67 proliferation index, tumor metastasis, and TNM grade were 0.8744, 0.7005, 0.7890, 0.8075, 0.8317, and 0.8301, respectively (all P<0.05) . Conclusion:hsa_circ_002082 is highly expressed in breast cancer tissue and peripheral blood, and hsa the potential to be a biomarker for the diagnosis of breast cancer.